Management of nonimmediate hypersensitivity reactions to drugs

Immunology and Allergy Clinics of North America

Volumn 34, Issue 3, 2014, Pages 473-487

  Roujeau, Jean Claude ^a,b   Haddad, Cynthia ^b,c   Paulmann, Maren ^b,d   Mockenhaupt, Maja ^b,d  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b RegiSCAR Network   (France)

^c Reference Center for Blistering Diseases HÔpital Henri Mondor   (France)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Drug reaction with eosinophilia and systemic symptoms (DRESS); Drug allergic liver injury (DALI); Drug induced nephritis (DIN); Drug induced vasculitis; Stevens Johnson syndrome (SJS); Toxic epidermal necrolysis (TEN)

Indexed keywords

ANTICONVULSIVE AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; IMMUNOGLOBULIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADVERSE DRUG REACTION; CLINICAL EXAMINATION; DERMATITIS; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE SEVERITY; DRESS SYNDROME; DRUG HYPERSENSITIVITY; DRUG IDENTIFICATION; DRUG INDUCED VASCULITIS; DRUG USE; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EARLY INTERVENTION; FOLLOW UP; HEALTH CARE FACILITY; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MACULOPAPULAR RASH; MEDICAL DECISION MAKING; PATIENT COUNSELING; PATIENT REFERRAL; PRIORITY JOURNAL; PRURITUS; REVIEW; SJOEGREN SYNDROME; SKIN MANIFESTATION; SKIN TEST; SYSTEMIC VASCULITIS; THERAPY DELAY; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; VASCULITIS; DISEASE MANAGEMENT; DRUG SURVEILLANCE PROGRAM; SEVERITY OF ILLNESS INDEX;

DISEASE MANAGEMENT; DRUG HYPERSENSITIVITY; HUMANS; PHARMACOVIGILANCE; SEVERITY OF ILLNESS INDEX;

EID: 84904046602     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2014.04.012     Document Type: Review

References (49)

1. Mayorga C., Sanz M.L., Gamboa P., et al. Invitro methods for diagnosing nonimmediate hypersensitivity reactions to drugs. JInvestig Allergol Clin Immunol 2013, 23:213-225.
2. Al-Nouri Z.L., George J.N. Drug-induced thrombocytopenia: an updated systematic review, 2012. Drug Saf 2012, 35:693-694.
3. Pichler W.J. Delayed drug hypersensitivity reactions. Ann Intern Med 2003, 139:683-693.
4. Hunziker T., Kunzi U.P., Braunschweig S., et al. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997, 52:388-393.
5. Rzany B., Mockenhaupt M., Baur S., et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. JClin Epidemiol 1996, 49(7):769-773.
6. Miller K.D., Lobel H.O., Satriale R.F., et al. Serious cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg 1986, 35(3):451-458.
7. Fontana R.J., Seeff L.B., Andrade R.J., et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010, 52(2):730-734.
8. Cerny A., Bertoli R. Drug allergic liver injury. Drug hypersensitivity 2007, 278-294. Karger, Basel (Switzerland). W.J. Pichler (Ed.).
9. Keller M., Spanou Z., Pichler W.J. Drug-induced interstitial nephritis. Drug hypersensitivity 2007, 295-305. Karger, Basel (Switzerland). W.J. Pichler (Ed.).
10. Muller P., Dubreil P., Mahé A., et al. Drug hypersensitivity syndrome in a West-Indian population. Eur J Dermatol 2003, 13(5):478-481.
11. Tennis P., Stern R.S. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997, 49(2):542-546.
12. Lionaki S., Hogan S.L., Falk R.J., et al. Vasculitis and anti-thyroid medication. Nephrol Dial Transplant 2008, 23(5):1766-1768.
13. Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Chem Immunol Allergy 2012, 97(1):1-17.
14. Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. JDtsch Dermatol Ges 2009, 7(2):142-160.
15. Sidoroff A. Acute generalized exanthematous pustulosis. Chem Immunol Allergy 2012, 97:139-148.
16. Kardaun S.H., Sekula P., Valeyrie-Allanore L., The RegiSCAR study group, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013, 169(5):1071-1080.
17. Praga M., González E. Acute interstitial nephritis. Kidney Int 2010, 77(11):956-961.
18. Xu B., Murray M. Flucloxacillin induced acute renal failure. Aust Fam Physician 2008, 37(12):1009-1011.
19. Kardaun S.H., Sidoroff A., Valeyrie-Allanore L., et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?. Br J Dermatol 2007, 156:609-611.
20. Phillips E., Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol 2007, 7(4):324-330.
21. Peyrière H., Dereure O., Breton H., et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?. Br J Dermatol 2006, 155(2):422-428.
22. Radic M., Martinovic Kaliterna D., Radic J. Drug-induced vasculitis: a clinical and pathological review. Neth J Med 2012, 70(1):12-17.
23. Bastuji-Garin S., Rzany B., Stern R.S., et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993, 129(1):92-96.
24. de Prost N., Ingen-Housz-Oro S., Duong T., et al. Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore) 2010, 89(1):28-36.
25. Bernal W., Auzinger G., Dhawan A., et al. Acute liver failure. Lancet 2010, 376:190-192.
26. Wei C.H., Chung-Yee Hui R., Chang C.J., et al. Identifying prognostic factors for drug rash with eosinophilia and systemic symptoms (DRESS). Eur J Dermatol 2011, 21(6):930-937.
27. Guégan S., Bastuji-Garin S., Poszepczynska-Guigné E., et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. JInvest Dermatol 2006, 126(2):272-276.
28. Haute Autorité de Santé. Nécrolyse épidermique (syndromes de Stevens-Johnson et de Lyell), protocole national de diagnostic et de soins. 2010. Available at:. Accessed on January 17, 2014. http://www.has-sante.fr.
29. Sassolas B., Haddad C., Mockenhaupt M., et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010, 88(1):60-68.
30. Mockenhaupt M., Viboud C., Dunant A., et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. JInvest Dermatol 2008, 128(1):35-44.
31. Mauri-Hellweg D., Bettens F., Mauri D., et al. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. JImmunol 1995, 155(1):462-472.
32. Klepser D.G., Collier D.S., Cochran G.L. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC Nephrol 2013, 14(1):150.
33. Garcia-Doval I., LeCleach L., Bocquet H., et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?. Arch Dermatol 2000, 136(3):323-327.
34. Chaponda M., Pirmohamed M. Hypersensitivity reactions to HIV therapy. Br J Clin Pharmacol 2011, 71(5):659-671.
35. Sekula P., Dunant A., Mockenhaupt M., RegiSCAR study group, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. JInvest Dermatol 2013, 133(5):1197-1204.
36. Chung W.H., Hung S.I., Yang J.Y., et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008, 14(12):1343-1350.
37. Roujeau J.C., Bastuji-Garin S. Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality. Ther Adv Drug Saf 2011, 2(3):87-94.
38. Huang Y.C., Li Y.C., Chen T.J. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol 2012, 167(2):424-432.
39. Valeyrie-Allanore L., Wolkenstein P., Brochard L., et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2010, 163(4):847-853.
40. Lee W.M., Hynan L.S., Rossaro L., Acute Liver Failure Study Group, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009, 137(3):856-864.
41. Squires R.H., Dhawan A., Alonso E., et al. Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial. Hepatology 2013, 57(4):1542-1549.
42. Sales I., Dzierba A.L., Smithburger P.L., et al. Use of acetylcysteine for non-acetaminophen-induced acute liver failure. Ann Hepatol 2013, 12(1):6-10.
43. González E., Gutiérrez E., Galeano C., et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int 2008, 73(8):940-946.
44. Raza M.N., Hadid M., Keen C.E., et al. Acute tubulointerstitial nephritis, treatment with steroid and impact on renal outcomes. Nephrology (Carlton) 2012, 17(8):748-753.
45. Mardivirin L., Valeyrie-Allanore L., Branlant-Redon E., et al. Amoxicillin-induced flare in patients with DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): report of seven cases and demonstration of a direct effect of amoxicillin on human herpesvirus 6 replication invitro. Eur J Dermatol 2010, 20(1):68-73.
46. Descamps V., Ben Saïd B., Sassolas B., groupe Toxidermies de la Société française de dermatologie, et al. Management of drug reaction with eosinophilia and systemic symptoms (DRESS). Ann Dermatol Venereol 2010, 137(11):703-708. [in French].
47. Dieterich D.T., Kotler D.P., Busch D.F., et al. Ganciclovir treatment of cytomegalovirus colitis in AIDS: a randomized, double-blind, placebo-controlled multicenter study. JInfect Dis 1993, 167(2):278-282.
48. Barbaud A., Collet E., Milpied B., Toxidermies group of the French Society of Dermatology, et al. Amulticentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol 2013, 168:555-562.
49. Chen Y.C., Chang C.Y., Cho Y.T., et al. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. JAm Acad Dermatol 2013, 68:459-465.